

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/663,999	09/16/2003	Kaname Ishibashi	224436	8529
23460	7590 06/02/2006		EXAMINER	
LEYDIG VOIT & MAYER, LTD			WHISENANT, ETHAN C	
TWO PRUDENTIAL PLAZA, SUITE 4900 180 NORTH STETSON AVENUE CHICAGO, IL 60601-6780		, 4900	ART UNIT	PAPER NUMBER
		1634		

DATE MAILED: 06/02/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)			
Supplemental Quayle	10/663,999	ISHIBASHI ET AL.			
Office Action Summary '	Examiner	Art Unit			
	Ethan Whisenant, Ph.D.	1634			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tirr vill apply and will expire SIX (6) MONTHS from a cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).			
Status					
1) Responsive to communication(s) filed on 17 Fe	<u>ebruary 2006</u> .				
·=	, -				
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims					
4) Claim(s) 16-22,25,26 and 29-33 is/are pending in the application.					
4a) Of the above claim(s) is/are withdrawn from consideration.					
5)⊠ Claim(s) <u>16-22,25,26 and 29-33</u> is/are allowed.					
	6) Claim(s) is/are rejected.				
	7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction and/or election requirement.				
o, are subject to restriction and, or	r oloollon roquiroment.				
Application Papers					
9) The specification is objected to by the Examine	r.				
10)⊠ The drawing(s) filed on <u>16 September 2003</u> is/are: a)□ accepted or b)⊠ objected to by the Examiner.					
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.					
Priority under 35 U.S.C. § 119					
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).					
a) ☑ All b) ☐ Some * c) ☐ None of:					
1. Certified copies of the priority documents have been received.					
 2. Certified copies of the priority documents have been received in Application No. <u>09/775,818</u>. 3. Copies of the certified copies of the priority documents have been received in this National Stage 					
application from the International Bureau (PCT Rule 17.2(a)).					
* See the attached detailed Office action for a list of the certified copies not received.					
Attachment(s)					
1) Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413)					
2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date 5) Notice of Informal Patent Application (PTO-152)					
Paper No(s)/Mail Date 6) Other:					

Application/Control Number: 10/663,999 Page 2

Art Unit: 1634

SUPPLEMENTAL QUAYLE ACTION

1. The applicant's response (filed 17 FEB 06) to the Office Action has been entered. Following the entry of the claim amendment(s), **Claim(s)** 16-22, 25-26 and 29-33 is/are pending.

•••SEQUENCE RULES•••

2. This application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth below:

Figures 1 and 2 comprise nucleic acid sequences which are not accompanied by a corresponding SEQ ID NO. Furthermore, the sequences present in Figures 1 and 2 are not present in the sequence listing.

See also the attached Notice to comply.

REASON FOR ALLOWANCE

3. Claim(s) 16-22, 25-26 and 29-33 is/are deemed to be allowable in light of the applicant's amendment filed 17 FEB 06 and the persuasive argument(s) therein.

CONCLUSION

- **Claim(s) 16-22, 25-26 and 29-33** is/are allowable for the reason(s) of record.
- 5. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ethan Whisenant, Ph.D. whose telephone number is

Application/Control Number: 10/663,999 Page 3

Art Unit: 1634

(571) 272-0754. The examiner can normally be reached Monday-Friday from 8:30AM - 5:30PM EST or any time via voice mail. If repeated attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ram Shukla, can be reached at (571) 272-0735.

The Central Fax number for the USPTO is (571) 273-8300. Before faxing any papers, please inform the examiner to avoid lost papers. Please note that the faxing of papers must conform with the Notice to Comply published in the Official Gazette, 1096 OG 30 (November 15, 1989).

ETHAN WHISENANT PRIMARY EXAMINER

Art Unit 1634

Application No.: 10/663,999

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

•	1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.			
0	2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).			
0	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).			
	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."			
0	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).			
	6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).			
0	7. Other:			
Applicant Must Provide:				

- An <u>initial</u> or substitute computer readable form (CRF) copy of the "Sequence Listing".
- An <u>initial</u> or substitute paper copy of the "Sequence Listing", as well as, an amendment directing its entry into the specification.
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).